25 Oct 2018 The company is well-positioned to benefit from the ongoing sale of its cannabis oils to patients through approved prescribers.
https://static1.*.com.au/thumbs/upload/News/Image/2018_10/757z468_1540438696_shutterstock_734579047.jpg Bod is an integrated cannabis business developing over-the-counter and prescription products Bod Australia Ltd (ASX:BDA) has secured the first approved prescription for its medicinal cannabis product MediCabilis with a patient through Cannabis Access Clinics, owned and operated by Biologics Research Institute Australia (BRIA).
Bod has also entered into a research collaboration agreement with Biologics to study the effects of MediCabilis on a broad range of patient outcomes.
The agreement will result in Bod’s sublingual cannabis wafer being available to patients in Cannabis Access’ networks once Bod completes the product’s phase I clinical trial.
Bod expects to benefit from additional sales of cannabis oil in the near-term and the agreement provides the company with access to Cannabis Access Clinics’ patient pool as well as feedback on MediCabilis’ efficacy as a treatment. ‘Large pool of potential patients’
Bod chief executive officer Jo Patterson said the agreement was very beneficial for Bod.
She said: “It has not only resulted in the company receiving its first prescription for MediCabilis, but also provides us with a large pool of potential patients and prescribers from the Cannabis Access Clinics network that will provide independent and ongoing feedback around our medicinal cannabis product offering.
“Cannabis Access Clinics has the most extensive network of doctors and patients in Australia and New Zealand and are a first mover in navigating the regulatory pathway for prescribing and monitoring medicinal cannabis therapies.
“We look forward to working with them and their network of physicians, patients and academics to continue our commitment to better educate the public around the benefits of medicinal cannabis.” READ: Bod Australia crosses a major milestone in developing cannabis wafer
Bod will gain access to Cannabis Access’ extensive patient treatment and monitoring platform across Australia and New Zealand.
The MediCabilis trial will provide feedback on the product’s ability to treat symptoms including anxiety, pain, post-chemotherapy nausea and vomiting, and epilepsy.
The data from the study will assist in refining phase II clinical trial parameters which will test specific indications of the product.
Cannabis Access Clinics medical director Dr Sanjay Nijhawan said:
“We place strong emphasis on ensuring medicinal cannabis is an appropriate treatment for our patients and undertake meticulous monitoring and data collection on an ongoing basis.
“We are pleased to offer our network of clinics as a research platform to help advance our understanding of how cannabis therapies work for particular patient groups.”
BDA Price at posting:
51.5¢ Sentiment: Buy Disclosure: Held
